Differential apoptotic response to the proteasome inhibitor bortezomib (VELCADE™, PS-341) in bax-deficient and p21-deficient colon cancer cells

Cancer Biology and Therapy

Volumn 2, Issue 6, 2003, Pages 694-699

  Yu, Jian ^a,b   Tiwari, Sagarika ^a   Steiner, Philipp ^c   Zhang, Lin ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Apoptosis; Bax; Bortezomib; Colon cancer; p21; p53; Proteasome inhibitor

Indexed keywords

ACETYLCYSTEINE; ACETYLLEUCYL LEUCYL NORLEUCINAL; ACETYLLEUCYL-LEUCYL-NORLEUCINAL; BAX PROTEIN, HUMAN; BORONIC ACID DERIVATIVE; BORTEZOMIB; CASPASE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; CYSTEINE PROTEINASE INHIBITOR; DRUG DERIVATIVE; LACTACYSTIN; LEUPEPTIN; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL STRAIN HCT116; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; GENETICS; HUMAN; METABOLISM; TIME;

ACETYLCYSTEINE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BORONIC ACIDS; CASPASES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HCT116 CELLS; HUMANS; LEUPEPTINS; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4043095823     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.6.573     Document Type: Article

References (45)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67:425-479.
2. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002; 82:373-428. (Pubitemid 34654457)
3. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996; 65:801-847. (Pubitemid 26255262)
4. Voges D, Zwickl P, Baumeister W. The 26S proteasome: A molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999; 68:1015-1068. (Pubitemid 29449214)
5. Adams, J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 2002; 14:628-634. (Pubitemid 35387373)
6. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001; 28:607-612. (Pubitemid 33134420)
7. Goldberg AL, Rock K. Not just research tools-proteasome inhibitors offer therapeutic promise. Nat Med 2002; 8:338-340. (Pubitemid 34407027)
8. Kisselev AF, Goldberg AL. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 2001; 8:739-758. (Pubitemid 32752454)
9. Anderson KC. Moving disease biology from the laboratory to the clinic. Semin Oncol 2002; 29:17-20.
10. Adams J. Proteasome inhibition: A novel approach to cancer therapy. Trends Mol Med 2002; 8:S49-54.
11. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8:2505-2511. (Pubitemid 34856332)
12. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-3076. (Pubitemid 32691956)
13. Kudo Y, Takata T, Ogawa I, Kaneda T, Sato S, Takekoshi T, et al. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000; 6:916-923. (Pubitemid 30159349)
14. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6:3719-3728.
15. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-2622. (Pubitemid 29269108)
16. An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000; 14:1276-1283.
17. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002; 1:1243-1253.
18. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NFkappaB as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277:16639-16647. (Pubitemid 34967682)
19. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-825. (Pubitemid 23346378)
20. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-299.
21. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101:1530-1534. (Pubitemid 36182530)
22. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997; 272:12893-12896. (Pubitemid 27216701)
23. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290:989-992, 2000.
24. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, et al. Tumor-cell resistance to death receptor - induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8:274-281. (Pubitemid 34250106)
25. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997; 3:1034-1036. (Pubitemid 27391962)
26. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104:263-269.
27. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 2003.
28. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: Clinical application. Clin Chem 2000; 46:673-683. (Pubitemid 30318423)
29. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7:673-682. (Pubitemid 32706358)
30. Bossy-Wetzel E, Green DR. Assays for cytochrome c release from mitochondria during apoptosis. Methods Enzymol 2000; 322:235-242. (Pubitemid 30482060)
31. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G(1) arrest in human cancer cells. Cancer Res 1995; 55:5187-5190.
32. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62:4996-5000. (Pubitemid 34984425)
33. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7:1419-1428. (Pubitemid 32708698)
34. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61:3535-3540. (Pubitemid 32694955)
35. Shah SA, Potter MW, McDade TP. Ricciardi R, Perugini RA, Elliott PJ, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82:110-122.
36. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001; 100:11-17. (Pubitemid 32802698)
37. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002; 62:1083-1086. (Pubitemid 34160291)
38. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99:14374-14379. (Pubitemid 35257679)
39. Fleming JA, Lightcap ES, Sadis S, Thoroddsen V, Bulawa CE, Blackman RK. Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341. Proc Natl Acad Sci USA 2002; 99:1461-1466. (Pubitemid 34136515)
40. Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002; 419:729-734. (Pubitemid 35177959)
41. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000; 20:2687-2695.
42. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl- 1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13:382-387. (Pubitemid 29108753)
43. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19:5923-5929. (Pubitemid 29399297)
44. Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 2002; 1:841-849.
45. Deverman, B. E., Cook, B. L., Manson, S. R., Niederhoff, R. A., Langer, E. M., Rosova, I., Kulans, L. A., Fu, X., Weinberg, J. S., Heinecke, J. W., Roth, K. A., and Weintraub, S. J. Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage. Cell, 111:51-62, 2002.